Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.

Summary

Across 285,124 participants from 46 randomized trials, a 5 mmHg systolic BP reduction lowered major cardiovascular events similarly in people with and without CKD (HR 0.91 vs 0.90), consistently across CKD stages and proteinuria strata. Benefits were attenuated in CKD patients with concomitant diabetes; class-specific effects mirrored the broader population. Median follow-up was 4.4 years.

Key Findings

• A 5 mmHg systolic BP reduction lowered major cardiovascular events in CKD (HR 0.91) and non-CKD (HR 0.90) alike.
• Effects were consistent across CKD stages, BP thresholds, and proteinuria status; class-specific effects paralleled the general population.
• Benefits were attenuated in CKD with concomitant diabetes, indicating a high-risk subgroup requiring tailored strategies.

Clinical Implications

Treat hypertension proactively across CKD stages, recognizing similar relative CVD risk reduction to non-CKD, while accounting for attenuated effects in CKD with diabetes. Drug class choices can follow general-population principles.

Limitations

• Heterogeneity in trial designs and BP targets; not primarily designed to optimize CKD-specific BP thresholds.
• Attenuation in CKD with diabetes may reflect residual confounding or differential risk pathways.

Future Directions

Define optimal BP targets and drug combinations in advanced CKD and CKD with diabetes; integrate renal safety and cardiorenal endpoints in pragmatic trials.